Skip to content

Clinical Research IO’s Survey Finds That Coronavirus is Disrupting Clinical Research Sites

Clinical Research IO‘s recent web survey found that COVID-19 is disrupting clinical research sites worldwide. The results are indicative of a significant slowdown in new drug development and long term effects on healthcare in general.

  • 25% of sites have stopped recruiting
  • Of the 75% that are continuing enrollment, about half (37%) are considering halting new patient enrollment
  • Sites that are still enrolling report on average, a 27% drop in recruitment

This means that aggregate recruiting is down by approximately 50% and studies will need double the time to fill enrollment. If half of the 75% stop recruiting, then clinical trial enrollment timelines will increase by four times.

Among the sites that are still conducting study visits, challenges remain.

  • Patient retention has started to fall, with an average decline of 9%,
  • The number of protocol deviations have risen, with an average increase of 4%
  • Nearly two thirds of sites (63%) have prohibited on site monitoring visits, thus inhibiting effective oversight by sponsors
  • These values are expected to increase with ongoing travel limitations and quarantines

In addition to identifying declining enrollment and retention rates, the survey revealed that over 90% of sites would utilize sponsor provided technology, meaning a direct electronic data capture tool combined with a document upload feature.

The web survey was fielded from March 19-23, 2020. A total of 73 sites across different therapeutic focuses participated.

by Maxine Lai Customer Success Manager at CRIO
Share this post
You may also find interesting
Explore our Blog
Running a Site

Ask Me Anything – Tools for Top Performing Sites

Kristen Bosse, Director of Product Development, is CRIO’s in-house product guru. In this Ask Me Anything, a CRIO expert roundup, Kristen discusses CRIO’s products, UX design and beta testing, and shares recommendations for sponsors looking to identify the best sites for their trials. What differentiates CRIO’s products from any other products on the market?  We...

Unlocking the Benefits of CRIO: eSource & eConsent Running a Site

Unlocking the Benefits of CRIO: eSource & eConsent

eConsent: The Benefits With the recent push toward Decentralized Clinical Trials, many sponsors are adopting eConsent. eConsent allows patients to consent electronically, whether in clinic or remotely, from the convenience of their home. eConsent offers sponsors, CROs investigators and patients these benefits: Removal of errors by ensuring completion of all fields Accuracy of date-times through...

In Big Diverse Corporate Office: Portrait of Beautiful Asian Manager Using Desktop Computer, Businesswoman Managing Company Operations, Analysing Statistics, Commerce Data, Marketing Plans. Running a Site

Data Blast from the Past: From Triplicate to eCRF

Jonathan Andrus, President & COO at CRIO, is an active thought-leader and presenter in the life sciences industry. He serves on the board and executive committee of the Society for Clinical Data Management (SCDM) and is co-lead with the Decentralized Trials and Research Alliance (DTRA) workstream initiative. The year was 1996 – the year that...